Johnson & Johnson’s IMAAVY Becomes First FDA-Approved wAIHA Treatment
Johnson & Johnson announced on August 24 that the FDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older previously or currently treated with corticosteroids. It is the first FDA-approved treatment for wAIHA.
The approval adds the first treatment option for this rare blood disorder and marks the expansion of an FcRn blocker approved for generalized myasthenia gravis (gMG) into another autoantibody-driven disease.
Key Highlights
- Durable hemoglobin response: 24% with IMAAVY vs 8% with placebo
- Mean hemoglobin increased by 1 g/dL at Week 1
- FcRn blockade designed to reduce pathogenic IgG
- Expansion beyond gMG into another autoantibody-driven disease
IMAAVY is an immunoselective neonatal Fc receptor (FcRn) blocker designed to reduce pathogenic IgG autoantibodies while preserving B-cell function. In wAIHA, this approach targets the autoantibodies that drive red blood cell destruction. In the Phase 2/3 ENERGY study, the approved 30 mg/kg dose achieved a higher rate of durable hemoglobin response than placebo.
The approval also highlights the potential of extending a validated mechanism across autoantibody-driven diseases. Indication expansion requires coordinated execution across translational strategy, clinical development, regulatory affairs, CMC, and business development.
Greenstaff Life Sciences supports pharmaceutical and biotech companies pursuing indication expansion and global development by connecting specialist talent from drug discovery through business development and helping strengthen capabilities at each stage.
Congratulations to Johnson & Johnson and everyone involved in the development of IMAAVY.